Edesa Biotech Advances on Two Fronts, Tackling Vitiligo and ARDS

TORONTO, ON – May 14, 2026 – Clinical-stage biopharmaceutical company Edesa Biotech, Inc. (Nasdaq:EDSA) today underscored its commitment to advancing its dual-front pipeline, reporting significant progress in its programs for vitiligo and Acute Respiratory Distress Syndrome (ARDS). The company's fiscal second-quarter 2026 results reveal a company in a crucial phase of execution, with preparations for a new clinical trial well underway and encouraging new data for its most advanced asset, even as research and development expenditures climb sharply.

Edesa is moving forward with plans for a Phase 2 clinical study of its drug candidate EB06 for vitiligo and has reported additional positive data from its Phase 3 study of paridiprubart for ARDS. This clinical momentum, however, comes at a cost, with operating expenses more than doubling compared to the same period last year, reflecting the capital-intensive nature of late-stage drug development.

A New Hope for Vitiligo Patients

One of the company's key focus areas is medical dermatology, where it aims to address the significant unmet need in vitiligo, an autoimmune disorder that causes patches of skin to lose their color. Affecting up to 2% of the global population, vitiligo currently has limited treatment options, with no approved systemic therapies designed to reverse the condition.

Edesa announced it is on track with preparations for an upcoming Phase 2 clinical study of EB06, a first-in-class monoclonal antibody. The company has contracted a clinical research organization, JSS Medical Research, and has begun outreach to clinical sites and investigators. Edesa reaffirmed its guidance that patient recruitment is expected to begin mid-year 2026, starting with sites in Canada where it has already received regulatory approval from Health Canada for the trial. An Investigational New Drug (IND) application with the U.S. FDA remains in process.

EB06 works by blocking CXCL10, a key inflammatory signaling protein that is highly expressed in vitiligo patients and is believed to be critical in both the initiation and maintenance of the disease. This novel mechanism offers a differentiated approach from the current market leader, Incyte's topical cream Opzelura®, the only FDA-approved treatment for vitiligo. While Opzelura has demonstrated commercial success, it carries a black-box warning for potential serious side effects, leaving an opening for therapies with a potentially more favorable safety profile. As a systemic biologic, EB06 could also offer a more convenient and effective solution for patients with extensive disease.

“Our second quarter progress reflects the meaningful strides we are making across both our medical dermatology and respiratory programs,” said Par Nijhawan, MD, Chief Executive Officer of Edesa. “In dermatology, our vitiligo program is on track and we are executing against our clinical milestones.”

Breakthrough Potential in Critical Care

Alongside its dermatology ambitions, Edesa is advancing a potentially life-saving treatment for Acute Respiratory Distress Syndrome (ARDS), a catastrophic form of respiratory failure with high mortality rates for which there are no approved pharmacological treatments. The standard of care remains largely supportive.

During the quarter, the company announced additional positive data from its Phase 3 study of paridiprubart. According to the release, the treatment benefits were consistent across different disease severity groups and in patients with serious comorbidities like acute kidney injury, pneumonia, and sepsis. This builds on previously reported results showing a statistically significant reduction in 28-day mortality.

Paridiprubart is a monoclonal antibody that targets Toll-like Receptor 4 (TLR4), a key mediator of the inflammatory cascade that leads to severe lung injury in ARDS. By blocking this pathway, the drug aims to quell the hyperinflammation that makes the condition so deadly. The promising Phase 3 data suggests paridiprubart could become a foundational therapy in a field starved for innovation.

“The new Phase 3 data for paridiprubart are particularly encouraging, and the consistent treatment benefits demonstrated across patient subgroups reinforce our confidence in this asset's potential to address critical care medicine's most challenging conditions,” Dr. Nijhawan stated.

The Price of Innovation

The clinical progress detailed in the report is mirrored in the company's financial statements, which show a significant ramp-up in investment. Total operating expenses for the quarter ended March 31, 2026, surged to $4.3 million, a steep increase from $1.6 million in the same period last year.

The primary driver of this increase was Research and Development (R&D) expenses, which jumped from $0.5 million to $2.8 million year-over-year. The company attributed this to manufacturing activities for EB06, preparations for its Phase 2 vitiligo study, and regulatory and manufacturing readiness for paridiprubart. This spending has led to a wider net loss of $4.2 million, or $0.49 per share, for the quarter, compared to a net loss of $1.6 million, or $0.30 per share, in the prior year.

Edesa’s Chief Financial Officer, Peter Weiler, confirmed this trend was expected. “As anticipated, operating expenses have edged higher in line with these preparations, and we expect that trend to continue as program activity builds,” he commented. As of March 31, 2026, Edesa reported having $10.0 million in cash and cash equivalents and $8.2 million in working capital to fund these ongoing operations.

Navigating a Competitive Landscape

Edesa is advancing its candidates in highly competitive and valuable markets. The vitiligo market alone is projected to reach $1.1 billion by 2030, attracting major pharmaceutical players. AbbVie and Pfizer are developing oral JAK inhibitors that have shown success in late-stage trials, positioning them as potential future competitors. However, EB06's unique first-in-class mechanism could carve out a significant niche if its safety and efficacy profile proves superior.

In the ARDS space, the landscape is defined more by failure and unmet need than by competition. A therapy that can demonstrate a clear mortality benefit, as paridiprubart's Phase 3 data suggests, would be a landmark achievement with immense market potential. To further disseminate its findings and explore opportunities, Edesa plans to participate in several key industry events in the coming months, including the American Thoracic Society (ATS) 2026 International Conference and the BIO International Convention.

For Edesa Biotech, the coming year represents a pivotal period. The initiation of the EB06 vitiligo trial and further data readouts for paridiprubart will be critical milestones that determine the company's trajectory, testing whether its significant investment in innovation can translate into transformative therapies for patients.